So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index

The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD. They are ranked below in descending order as to their performances MTD (month-to-date).

  1. Mind Medicine (MNMD): down 2.3% MTD
  2. Seelos (SEEL): down 4.6% MTD
  3. Compass Pathways (CMPS): down 10.8% MTD
  4. Incannex Healthcare (IXHL): down 11.3% MTD
  5. GH Research (GHRS): down 15.5% MTD
    • is primarily focused on the use of mebufotenin*, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine but is better known by its nickname, “The Toad”.
  6. Atai (ATAI): down 18.4% MTD

*Read 10 Psychedelic Substances And The 36 Companies Researching Them for a description of each of the psychedelic-based compounds mentioned in this article.


The munKNEE Psychedelic Drug Stocks Index is down 11.9% MTD but is up 13.6% YTD.

If you are interested in this category, consider the  AdvisorShares Psychedelic ETF (PSIL), which consists of 23 such stocks (of which the majority have market capitalizations of less than $50M). It is down 8.2% MTD and is now down 3.2% YTD.

More By This Author:

Cronos Brands' Q2 Financials Show Major Reduction In Net Loss
Curaleaf Q2 Financials Report 31% Increase In Net Loss
Canopy Growth Q1 Financial Report: Cannabis Revenue Down 26%

Disclosure: None 

Visit and register to receive our free Market Intelligence Report newsletter ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.